Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
Abbott plans acquisition of Exact Sciences and strengthens cancer diagnostics business
Abbott will acquire Exact Sciences for billions to expand its cancer diagnostics offering. The stock is little changed in premarket trading, even though the acquisition puts the company in the spotlight. » Plus sur finanzen.net
Abbott disappoints with Q3 numbers, stock worst performer in S&P 500
Abbott increased revenue in the third quarter by nearly 7% to 11.37 billion USD, slightly missing analysts' expectation of 11.39 billion USD. Adjusted earnings per share of 1.30 USD met expectations, and organic revenue growth was 5.5%. The full-year guidance for organic revenue growth was reaffirmed at 7.5–8.0% and the EPS range was narrowed to 5.12–5.18 USD; the stock fell about 3% after the release and finished at the bottom of the S&P 500. » Plus sur deraktionaer.de
USC Trojans need to close games as Matt Leinart warns Lincoln Riley is on the hot seat
Matt Leinart says USC must improve from last season by winning more than eight games and learning to finish close contests, noting five one-possession losses and that Lincoln Riley is on the hot seat entering 2025. The Trojans return QB Jayden Maiava and face a tough Big Ten slate including Ohio State, Penn State, Oregon, Michigan and Notre Dame, with Leinart saying improvement rather than a playoff berth is the clearest measure of success. Off the field, Leinart discusses his partnership with Abbott’s Ensure Max Protein and his involvement in pickleball with the New Jersey Fives. » Plus sur forbes.com
Données financières de l'entreprise
| (EUR) | mars 2026 | |
|---|---|---|
| Chiffre d'affaires | 27,61 k | 90,10 % |
| Bénéfice brut | -7,99 k | 103,59 % |
| Bénéfice net | -127,64 k | 156,88 % |
| EBITDA | -139,57 k | 592,55 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 2,19 M € |
Nombre d'actions | 101,29 M |
Plus haut/bas sur 52 semaines | 0,0679 € - 0,013 € |
| Dividendes | Non |
Bêta | 0,32 |
Ratio P/E | -4,62 |
Ratio PEG | 0,07 |
Ratio P/B | 46,70 |
Ratio P/S | 63,25 |
Profil de l'entreprise
Avricore Health Inc. ist im Bereich Gesundheitsdaten und Point-of-Care-Technologien in Kanada tätig. Es bietet HealthTab an, eine laborgenaue Point-of-Care-Testplattform für Apotheken. Das Unternehmen unterhält strategische Partnerschaften mit Shoppers Drug Marts und Abbott. Das Unternehmen war früher als Vanc Pharmaceuticals Inc. bekannt und änderte im Oktober 2018 seinen Namen in Avricore Health Inc. Avricore Health Inc. wurde 1996 gegründet und hat seinen Sitz in Vancouver, Kanada.
| Nom | AVRICORE HEALTH INC. |
| PDG | Rodger Seccombe |
| Siège social | Vancouver,
bc Canada |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 19/06/2009 |
| Employés | 26 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
Tsxv | AVCR.V |
Pnk | AVCRF |
Frankfurt | 8VP1.F |
Découvrir des actifs
Les actionnaires de AVRICORE HEALTH INC. investissent également dans les actifs suivants

![Call auf AMD [HSBC Trinkaus & Burkhardt GmbH] Logo](https://img.parqet.com/assets/fallback.png)